All In Biotech

NDA 019845 · Novartis

Betoptic S

Betaxolol Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Dec 29, 1989

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 1 recruiting

FAERS reports

521

400 serious, 44 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 22, 2025.

BETOPTIC S ® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. BETOPTIC S is a beta-adrenergic receptor inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor inhibitor, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic receptor inhibitors reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function. When instilled in the eye, BETOPTIC S has the action of reducing elevated...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BETOPTIC S · BETAXOLOL HYDROCHLORIDE EQ 0.25% BASE · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Betaxolol" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall67
  • dyspnoea61
  • drug ineffective50
  • pain39
  • dizziness38
  • asthma35
  • eye irritation35
  • fatigue34
  • nausea33
  • haemorrhage32
  • headache31
  • hypersensitivity31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200511
20066
200710
20088
200911
201011
201113
201213
201310
20149
201514
201619
201737
201848
201964
202031
202124
202243
202331
202455
202526
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betoptic S (Betaxolol HCl)

2024 spending

$3.7M

Beneficiaries

1,971

7,033 claims

Per beneficiary

$1,875

$35.61 per unit

View as table
YearSpending
2020$6,215,153
2021$5,501,373
2022$4,820,042
2023$4,403,689
2024$3,695,025

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 231 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.